Last updated 2026-08-23
- Raised $1.4M Seed round led by AION Labs, Sep 2025
Total raised
$1.4M
Last: Undisclosed Round 2024-12
Stage
Pre-Seed
Founded
2024
Headcount
7
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
At Cellyrix, we are on a mission to introduce a new modality into cancer treatment by harnessing the power of cutting-edge technologies. Tumor heterogeneity, a fundamental aspect of cancer, lies at the heart of treatment challenges such as therapy resistance, metastasis, and relapse. Leveraging breakthroughs in single-cell sequencing and artificial intelligence, we are pioneering a novel approach to unlock insights into intra-tumor heterogeneity and develop innovative cancer treatments.
Funding history · 1 round · $1.4M total
1 event/round · $1.4M Total Funding: $1.4M in Private Equity
Sep 2025
★ AION Labs★ AstraZeneca★ Amiti Ventures★ Israel Biotech Fund★ one unnamed investor★ Teva Pharmaceutical Industries
Headcount over time
7 employees (2026-09) · 1 point
Offices
Rehovot, Israel · HQ / main office
Q&A
- What is Cellyrix Therapeutics' primary mission?
- Cellyrix Therapeutics is on a mission to introduce a new modality into cancer treatment by harnessing cutting-edge technologies. They aim to unlock insights into intra-tumor heterogeneity and develop innovative cancer treatments.
- When was Cellyrix Therapeutics founded?
- Cellyrix Therapeutics was founded in December 2024.
- How many employees does Cellyrix Therapeutics currently have?
- Cellyrix Therapeutics currently has 1-10 employees.
- What is Cellyrix Therapeutics' current funding stage?
- Cellyrix Therapeutics is currently in the Pre-Seed funding stage.
- Which investor participated in Cellyrix Therapeutics' December 2024 funding round?
- AION Labs participated in Cellyrix Therapeutics' funding round in December 2024.
- What technologies does Cellyrix Therapeutics leverage in its approach?
- Cellyrix Therapeutics leverages breakthroughs in single-cell sequencing and artificial intelligence.
- What is the primary sector of Cellyrix Therapeutics?
- Cellyrix Therapeutics' primary sector is Health Tech & Life Sciences.
- Where is Cellyrix Therapeutics headquartered?
- Cellyrix Therapeutics is headquartered in Rehovot, Center District, Israel.
Team · 8
Eran Kotler
Founder · CEO and Co-founder
Avishai Gavish
Founder · Scientific co-founder
Dganit Bar
Founder · CSO and Co-Founder
Mordechai Applebaum
COO
Michael Mints
head of Comp Bio
Itay Tirosh
Principal Investigator, Department of Molecular Cell Biology, Weizmann Institute of Science
Eliezer Van Allen
Chief of the Division of Population Sciences, Dana-Farber Cancer Institute and Professor of Medicine, Harvard Medical School
David Sidransky
Professor of Oncology and Cellular & Molecular Medicine, Johns Hopkins University School of Medicine
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Business model
B2B
Highlights
Verified
Tags
drug-discoverycancer-therapypharmaceuticalsdrug-developmentcancerbiotechnologyartificial-intelligence
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | cellyrix.com/ |
|---|---|
| linkedin.com/company/103523835 |
Identifiers & details
| Legal name | CELLYRIX THERAPEUTICS LTD |
|---|---|
| Founded | 2024-12 |
| Employees (exact) | 7 |
Radar intelligence
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 517076782 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2024-12-09 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 7 — shares_capital (4), annual_report (2), people (1) |
| Registered address | אופנהיימר 4 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2025-09-30 | הקצאת מניות |
| 2025-09-29 | שינוי בהרכב הון - מניות-פיצול מניה |
| 2025-11-25 | שינוי בהרכב הון - מניות-הפחתת הון מוקצה |
| 2025-11-20 | דו~ח שנתי-שינוי בהוראות בתקנון |
| 2025-11-20 | דו~ח שנתי-הוספת דירקטור |
| 2025-09-17 | העברת מניות |
| 2025-09-17 | עדכון בעלי תפקידים |